Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Announces Special Window for Share Transfer & Dematerialization

Gujarat Themis Biosyn opens a one-year special window (Feb 5, 2026 - Feb 4, 2027) for dematerializing physical shares and re-lodging transfer requests for shares transacted before April 1, 2019. This complies with a SEBI circular to regularize pending transfer cases.

Gujarat Themis Biosyn: Certificate Under SEBI (Depositories) Regulations, 2018 For Q4FY26

Gujarat Themis Biosyn Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate was received from MUFG Intime India Pvt. Ltd., confirming dematerialisation and listing of securities.

Gujarat Themis Biosyn Limited: Trading Window Closure from April 1, 2026

Gujarat Themis Biosyn Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the board meeting to approve the Q4 FY26 audited financial results.

Gujarat Themis Biosyn Ltd. Publishes Newspaper Advertisement for Postal Ballot Notice

Gujarat Themis Biosyn Limited published a newspaper notice for its postal ballot on March 19, 2026. Members will vote on re-appointing Mrs. Kirandeep Madan and approving related party transactions with Themis Medicare Limited. E-voting is open from March 19 to April 17, 2026.

Gujarat Themis Biosyn: Postal Ballot for Director Re-appointment & Related Party Transactions

Gujarat Themis Biosyn is seeking member approval via postal ballot for the re-appointment of Mrs. Kirandeep Madan as an Independent Director for a second term (May 1, 2026 - April 30, 2031). It also seeks approval for related party transactions with Themis Medicare Limited up to ₹50 Crores for FY26-27. E-voting is open from March 19 to April 17, 2026.

Gujarat Themis Biosyn Ltd: Shareholders Approve Special Resolution for Director Appointment

Gujarat Themis Biosyn Limited shareholders approved the appointment of Mr. Rajneesh Anand as Non-Executive Non-Independent Director via postal ballot and e-voting. The resolution passed with 77,218,083 votes in favour out of 77,954,837 total votes polled.

Gujarat Themis Biosyn Limited Announces Unaudited Financial Results for Q3 FY26

Gujarat Themis Biosyn Limited reported unaudited financial results for Q3 FY26. For the nine months ended Dec 31, 2025, total income was ₹1753.074 lakh and net profit was ₹3.386 lakh. For the quarter ended Dec 31, 2025, total income was ₹566.015 lakh and net loss was ₹64.548 lakh. Board approved results on Feb 5, 2026.

Gujarat Themis Biosyn Q3 Results: Net Profit Declines to ₹1,246.46 Lakhs

Gujarat Themis Biosyn reported Q3 net profit of ₹1,246.46 lakhs, down from ₹1,297.23 lakhs YoY. Nine-month profit was ₹3,579.03 lakhs, down from ₹3,677.35 lakhs. Ms. Kirandeep Madan was re-appointed as Independent Director. Mr. Krupesh Patel appointed as CFO from April 1, 2026.

Gujarat Themis Biosyn Presents Q3 FY26 Investor Presentation

Gujarat Themis Biosyn reported Q3 FY26 revenue of ₹43.4 Cr (up 10% YoY) and PAT of ₹12.5 Cr. Nine-month PAT stood at ₹35.79 Cr. The company completed a new fermentation facility and is setting up a hybrid renewable power plant. R&D spend was 3% of revenue.

Gujarat Themis Biosyn Approves Q3 Unaudited Results; Appoints New CFO

Gujarat Themis Biosyn approved unaudited Q3 results. Ms. Kirandeep Madan reappointed as Independent Director from May 1, 2026. Mr. Krupesh Patel appointed CFO from April 1, 2026, replacing Mr. Bhavik Shah who transitions to a new role.

Gujarat Themis Biosyn: Re-appoints Independent Director, Appoints New CFO

Gujarat Themis Biosyn approved unaudited financial results for Q3 FY26. Ms. Kirandeep Madan re-appointed as Non-Executive Woman Independent Director from May 1, 2026. Mr. Krupesh Patel appointed CFO & KMP effective April 1, 2026.

Gujarat Themis Biosyn Q3 FY26 Results: Profit Rs 1246 Lakhs; Key Appointments Approved

Gujarat Themis Biosyn reported Q3 FY26 net profit of ₹1,246.46 lakhs. The board re-appointed Ms. Kirandeep Madan as Non-Executive Woman Independent Director for a five-year term starting May 1, 2026. Mr. Krupesh Patel will be the new CFO from April 1, 2026, succeeding Mr. Bhavik Shah who moves to a new role.

Gujarat Themis Biosyn: No Physical Share Transfer Requests in Dec 2025

Gujarat Themis Biosyn Limited reports no physical share transfer re-lodgement requests in December 2025, as per SEBI guidelines. The company's RTA confirmed the absence of such cases.

Gujarat Themis Biosyn Publishes Newspaper Ad for Postal Ballot Notice

Gujarat Themis Biosyn Limited published its Postal Ballot Notice on January 8, 2026, in 'Western Times'. The notice seeks member approval for appointing Mr. Rajneesh Anand as a Non-Executive Non-Independent Director via e-voting. The voting period is from January 8 to February 6, 2026.

Gujarat Themis Seeks Approval for Rajneesh Anand's Director Appointment

Gujarat Themis Biosyn Limited is seeking shareholder approval for Mr. Rajneesh Anand's appointment as a Non-Executive Non-Independent Director for a five-year term from November 10, 2025, to November 9, 2030. Remote e-voting is open from January 8 to February 6, 2026. Mr. Anand will receive ₹10 lakh monthly as professional fees.

Gujarat Themis Biosyn Ltd Files SEBI Reg 74(5) Certificate for Q3 FY26

Gujarat Themis Biosyn Limited submitted its SEBI Regulation 74(5) certificate for the quarter ending December 31, 2025. The company confirmed processing of dematerialised securities received from depository participants.

Gujarat Themis Biosyn Ltd: Reminder for Special Window for Physical Share Transfer

Gujarat Themis Biosyn Limited reminds shareholders about its special window for re-lodging transfer requests for physical shares, open until January 6, 2026. This applies to requests rejected before April 1, 2019. Transfers will be processed in dematerialized form.

Gujarat Themis Biosyn: No Physical Share Transfer Requests in Oct-Nov 2025

Gujarat Themis Biosyn Limited reported no cases for re-lodgement of transfer requests of physical shares for October and November 2025. This update is as per SEBI guidelines and confirmed by the company's RTA, MUFG Intime India Private Limited.

Gujarat Themis Biosyn Closes Trading Window from Jan 1, 2026 for Q4 FY26 Results

Gujarat Themis Biosyn Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the board declares financial results for the quarter ending December 31, 2025. The exact date of the board meeting will be announced later.

Gujarat Themis Biosyn Limited Announces Un-Audited Financial Results

Gujarat Themis Biosyn Limited's Board approved the un-audited financial results for the quarter and half year ended 30th September, 2025.The results and limited review reports are available on the company's website.

Gujarat Themis Biosyn Investor Presentation for Q2 & H1 FY26

Gujarat Themis Biosyn's Q2 FY26 revenue rose by 22% to ₹42.3 Cr, EBITDA by 36.3% to ₹20.9 Cr, and PAT by 35.3% to ₹14.3 Cr. The company has completed its fermentation block expansion.

GUJTHEM: Rajneesh Anand appointed as Additional Non-Executive Director

Gujarat Themis Biosyn Limited approved unaudited financial results for the quarter and half year ended September 30, 2025. Appointed Mr. Rajneesh Anand as an Additional Non-Executive Non-Independent Director for 5 years.

Gujarat Themis Biosyn Reports Strong Q2 FY26 Results, Appoints New Director, and Expands Fermentation Capacity

Gujarat Themis Biosyn reported strong Q2 FY26 results with increased profit. The company appointed Mr. Rajneesh Anand as a director and significantly expanded its fermentation capacity, commencing new product production.

GUJTHEM Approves Unaudited Financial Results & Appoints Additional Director

Gujarat Themis Biosyn (GUJTHEM) approves unaudited financial results for the quarter ended September 30, 2025, and appoints Mr. Rajneesh Anand as an Additional Non-Executive Non-Independent Director.

Gujarat Themis Biosyn commences commercial production at expanded Vapi fermentation plant, doubling capacity

Gujarat Themis Biosyn commenced commercial production at its expanded Vapi fermentation plant on October 18, 2025, doubling capacity from 450 KL to 990 KL for Rifamycin-S and Rifamycin-O, aiming to capitalize on growth opportunities.

Reminder: Special window for re-lodgement of physical share transfer requests

Gujarat Themis Biosyn Limited reminds shareholders about the special window for re-lodgement of transfer requests for physical shares open until 6 January 2026.

Report on Special Window for Re-lodgement of Transfer Requests

Gujarat Themis Biosyn Limited reports on the special window for re-lodgement of physical share transfer requests for July, August, and September 2025, noting no requests received in September.

Clarification on Volume Increase

GUJTHEM Announces Dividend, Director Appointments & Re-designation

Gujarat Themis Biosyn Announces 44th AGM, Annual Report & Future Plans

Gujarat Themis Biosyn Reports Q1 FY26 Results, Scraps Merger, Commissions New API Plant, and Announces Board Changes